RBC Capital Out Negative on Gilead Sciences (GILD), 'see the stock as lacking'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. GLOB
2. AMAT
3. ELUT
4. RDDT
5. XOS
6. DGNX
7. ZNTL
8. ETON
9. SPY
10. UCB

Go back to RBC Capital Out Negative on Gilead Sciences (GILD), 'see the stock as lacking'

AstraZeneca (AZN) Gains After Gilead Sciences (GILD) Study in Lung Cancer Fails

January 22, 2024 8:47 AM EST

AstraZeneca (NASDAQ: AZN) Gains After Gilead Sciences (NASDAQ: GILD) Study in Lung Cancer Fails

GILD -9%AZN +3% Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in... More

Gilead Sciences (GILD) Sinks 11% After Lung Cancer Study Fails

January 22, 2024 8:42 AM EST

Gilead Sciences Sinks 11% After Lung Cancer Study Fails

A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology. The safety profile for Trodelvy was consistent with prior studies. Trodelvy was generally well tolerated, and no new safety signals... More

Gilead Sciences (GILD) Provides Update on Phase 3 EVOKE-01 Study

January 22, 2024 8:30 AM EST

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology. The safety profile for Trodelvy was consistent with prior studies. Trodelvy was... More